Chikungunya media information
PLEASE NOTE: All assets on this page are intended for use by U.S. media professionals only.
February 14, 2025
Bavarian Nordic Receives U.S. FDA Approval of Chikungunya Vaccine for Persons Aged 12 and Older
Bavarian Nordic is proud to introduce VIMKUNYATM, the first virus-like particle (VLP) single-dose chikungunya vaccine approved by the U.S. Food and Drug Administration (FDA) for individuals aged 12 and older. This milestone marks a significant advancement in addressing the growing global health threat of chikungunya, a mosquito-borne virus linked to severe joint pain, fever, and other debilitating symptoms.
VIMKUNYA is designed to help protect against chikungunya, particularly for travelers visiting endemic regions.
Commercial availability of VIMKUNYA in the U.S. is anticipated in the first half of 2025.
For additional details, read the full press release below.